FATE
Fate Therapeutics, Inc. NASDAQ Listed Oct 1, 2013$2.09
+6.63%
vs $1.96
Mkt Cap $248.3M
52w Low $0.92
60.9% of range
52w High $2.84
50d MA $1.87
200d MA $1.35
P/E (TTM)
-1.8x
EV/EBITDA
—
P/B
1.2x
Debt/Equity
0.4x
ROE
-65.8%
P/FCF
-2.2x
RSI (14)
25.20
ATR (14)
$0.21
Beta
2.24
50d MA
$1.87
200d MA
$1.35
Avg Volume
4.0M
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
12278 Scripps Summit Drive · San Diego, CA 92131 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.30 | -0.26 | +13.3% | 2.25 | -2.7% | -5.3% | -10.8% | -7.4% | -1.7% | +9.2% | — |
| May 12, 2026 | BMO | — | — | — | 2.18 | +0.5% | +3.2% | -5.3% | -10.8% | -7.4% | -1.7% | — |
| Feb 26, 2026 | BMO | -0.27 | -0.27 | +0.0% | 1.56 | -0.6% | -5.1% | +1.4% | -8.7% | +5.8% | -4.8% | — |
| Nov 13, 2025 | BMO | -0.29 | -0.27 | +6.9% | 0.99 | -0.7% | -2.9% | +0.9% | +4.8% | +2.9% | -4.8% | — |
| Aug 12, 2025 | BMO | -0.35 | -0.29 | +17.1% | 0.94 | +1.5% | +20.7% | -5.3% | +1.9% | +10.1% | -5.0% | — |
| May 13, 2025 | BMO | -0.39 | -0.32 | +17.9% | 1.00 | +5.0% | -4.0% | +5.2% | +5.9% | +14.0% | +2.5% | — |
| Mar 5, 2025 | BMO | -0.44 | -0.31 | +29.5% | 0.91 | +0.5% | +14.9% | -2.9% | -8.2% | +3.6% | +5.2% | — |
| Nov 12, 2024 | BMO | -0.42 | -0.40 | +4.8% | 2.38 | +2.9% | -8.8% | -4.1% | -2.9% | +12.4% | -4.0% | — |
| Aug 13, 2024 | BMO | -0.47 | -0.33 | +29.8% | 3.34 | +1.2% | -2.1% | +3.7% | +0.3% | +6.8% | +1.1% | — |
| May 9, 2024 | BMO | -0.47 | -0.47 | +0.0% | 3.90 | -1.3% | +4.6% | +1.7% | +1.7% | +0.5% | -2.4% | — |
| Feb 26, 2024 | BMO | -0.57 | -0.45 | +21.1% | 6.95 | +8.8% | +7.3% | -4.3% | -0.7% | +9.2% | -8.5% | — |
| Nov 8, 2023 | BMO | -0.59 | -0.46 | +22.0% | 2.33 | +3.0% | -8.6% | -3.3% | -3.4% | +16.1% | +7.4% | — |
| Aug 8, 2023 | BMO | -0.58 | -0.54 | +6.9% | 3.53 | -0.8% | -3.7% | -4.1% | -5.2% | -2.3% | -3.0% | — |
| May 3, 2023 | AMC | -0.55 | -0.19 | +65.5% | 6.32 | -5.1% | -2.4% | -7.9% | -4.0% | -1.1% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Jefferies | Reiterates | Buy | — | $1.73 | $1.70 | -1.7% | +9.2% | -2.6% | +14.1% | +7.1% | -4.4% |
| Oct 31 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.29 | $1.40 | +8.5% | +4.7% | -6.7% | -5.6% | -8.4% | -4.6% |
| Oct 27 | Wedbush | Upgrade | Neutral → Outperform | — | $1.65 | $1.75 | +6.1% | -6.1% | -3.9% | -10.1% | -3.7% | +4.7% |
| Oct 27 | Needham | Maintains | Hold → Hold | — | $1.65 | $1.75 | +6.1% | -6.1% | -3.9% | -10.1% | -3.7% | +4.7% |
| Aug 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $0.94 | $0.95 | +1.5% | +20.7% | -5.3% | +1.9% | +10.1% | -5.0% |
| Jun 12 | Needham | Maintains | Hold → Hold | — | $1.55 | $1.50 | -3.2% | -9.7% | -9.3% | -2.4% | -3.2% | +0.8% |
| May 14 | Baird | Maintains | Neutral → Neutral | — | $1.00 | $1.05 | +5.0% | -4.0% | +5.2% | +5.9% | +14.0% | +2.5% |
| May 14 | Needham | Maintains | Hold → Hold | — | $1.00 | $1.05 | +5.0% | -4.0% | +5.2% | +5.9% | +14.0% | +2.5% |
| May 14 | Barclays | Maintains | Overweight → Overweight | — | $1.00 | $1.05 | +5.0% | -4.0% | +5.2% | +5.9% | +14.0% | +2.5% |
| Mar 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $0.91 | $0.91 | +0.5% | +14.9% | -2.9% | -8.2% | +3.6% | +5.2% |
| Mar 6 | Wedbush | Maintains | Neutral → Neutral | — | $0.91 | $0.91 | +0.5% | +14.9% | -2.9% | -8.2% | +3.6% | +5.2% |
| Mar 6 | Needham | Maintains | Hold → Hold | — | $0.91 | $0.91 | +0.5% | +14.9% | -2.9% | -8.2% | +3.6% | +5.2% |
| Mar 6 | Stifel | Maintains | Hold → Hold | — | $0.91 | $0.91 | +0.5% | +14.9% | -2.9% | -8.2% | +3.6% | +5.2% |
| Aug 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.91 | $3.96 | +1.3% | -3.6% | +1.9% | +1.0% | -7.5% | -2.2% |
| Jun 17 | Piper Sandler | Upgrade | Neutral → Overweight | — | $3.61 | $3.93 | +8.9% | -1.1% | -4.5% | +5.3% | +4.7% | +2.1% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.24 | $4.26 | +0.5% | -2.4% | -5.8% | +0.3% | -5.4% | -1.4% |
| May 10 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.90 | $3.85 | -1.3% | +4.6% | +1.7% | +1.7% | +0.5% | -2.4% |
| May 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $3.90 | $3.85 | -1.3% | +4.6% | +1.7% | +1.7% | +0.5% | -2.4% |
| May 10 | Wedbush | Maintains | Neutral → Neutral | — | $3.90 | $3.85 | -1.3% | +4.6% | +1.7% | +1.7% | +0.5% | -2.4% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.90 | $3.85 | -1.3% | +4.6% | +1.7% | +1.7% | +0.5% | -2.4% |
| May 6 | Wedbush | Maintains | Neutral → Neutral | — | $4.06 | $4.08 | +0.5% | +3.9% | -8.1% | -4.6% | +5.4% | +4.6% |
| Apr 23 | Wedbush | Maintains | Neutral → Neutral | — | $4.78 | $4.79 | +0.2% | -5.0% | -5.3% | -10.0% | -1.8% | +6.3% |
| Mar 28 | BofA Securities | Maintains | Underperform → Underperform | — | $7.34 | $7.27 | -1.0% | +0.0% | -3.5% | -4.0% | +3.1% | -0.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.04 | $6.83 | -3.0% | -0.6% | +6.1% | +0.0% | -11.0% | +3.9% |
| Feb 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.95 | $7.56 | +8.8% | +7.3% | -4.3% | -0.7% | +9.2% | -8.5% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $6.95 | $7.56 | +8.8% | +7.3% | -4.3% | -0.7% | +9.2% | -8.5% |
| Feb 27 | Oppenheimer | Maintains | Perform → Perform | — | $6.95 | $7.56 | +8.8% | +7.3% | -4.3% | -0.7% | +9.2% | -8.5% |
| Feb 27 | BMO Capital | Maintains | Market Perform → Market Perform | — | $6.95 | $7.56 | +8.8% | +7.3% | -4.3% | -0.7% | +9.2% | -8.5% |
| Feb 27 | Wedbush | Maintains | Neutral → Neutral | — | $6.95 | $7.56 | +8.8% | +7.3% | -4.3% | -0.7% | +9.2% | -8.5% |
| Nov 20 | Mizuho | Maintains | Buy → Buy | — | $2.43 | $2.44 | +0.4% | +7.0% | -5.8% | -2.4% | -1.3% | -3.4% |
| Nov 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.06 | $2.01 | -2.4% | -3.4% | +16.1% | +7.4% | -4.0% | +2.1% |
| Nov 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $2.33 | $2.40 | +3.0% | -8.6% | -3.3% | -3.4% | +16.1% | +7.4% |
| Nov 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $2.33 | $2.40 | +3.0% | -8.6% | -3.3% | -3.4% | +16.1% | +7.4% |
| Nov 9 | Wedbush | Maintains | Neutral → Neutral | — | $2.33 | $2.40 | +3.0% | -8.6% | -3.3% | -3.4% | +16.1% | +7.4% |
| Sep 7 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $2.60 | $2.55 | -1.9% | -5.0% | +0.4% | -1.6% | +4.1% | -5.9% |
| Aug 16 | Truist | Maintains | Hold → Hold | — | $2.93 | $2.90 | -1.0% | -4.8% | -0.4% | +0.0% | -1.8% | -2.6% |
| Aug 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.40 | $3.37 | -0.9% | -4.1% | -5.2% | -2.3% | -3.0% | -4.8% |
| Aug 10 | Barclays | Maintains | Overweight → Overweight | — | $3.40 | $3.37 | -0.9% | -4.1% | -5.2% | -2.3% | -3.0% | -4.8% |
| Aug 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.53 | $3.50 | -0.8% | -3.7% | -4.1% | -5.2% | -2.3% | -3.0% |
| Aug 9 | EF Hutton | Maintains | Buy → Buy | — | $3.53 | $3.50 | -0.8% | -3.7% | -4.1% | -5.2% | -2.3% | -3.0% |
| May 5 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.17 | $6.28 | +1.8% | -7.9% | -4.0% | -1.1% | -0.9% | -1.5% |
| May 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $6.32 | $6.00 | -5.1% | -2.4% | -7.9% | -4.0% | -1.1% | -0.9% |
| May 4 | Stifel | Maintains | Hold → Hold | — | $6.32 | $6.00 | -5.1% | -2.4% | -7.9% | -4.0% | -1.1% | -0.9% |
| Mar 2 | Citigroup | Maintains | Buy → Buy | — | $6.09 | $6.10 | +0.2% | +0.0% | +0.3% | -4.7% | -2.4% | -1.1% |
| Mar 1 | EF Hutton | Maintains | Buy → Buy | — | $6.12 | $6.16 | +0.7% | -0.5% | +0.0% | +0.3% | -4.7% | -2.4% |
| Jan 24 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $5.55 | $5.42 | -2.3% | -2.2% | -0.6% | -1.9% | +11.7% | -3.2% |
| Jan 9 | Goldman Sachs | Maintains | Sell → Sell | — | $4.24 | $4.32 | +1.9% | +24.3% | +4.2% | +4.2% | +2.4% | -7.8% |
| Jan 6 | Truist | Downgrade | Buy → Hold | — | $11.00 | $4.38 | -60.2% | -61.5% | +24.3% | +4.2% | +4.2% | +2.4% |
| Jan 6 | Piper Sandler | Downgrade | Overweight → Neutral | — | $11.00 | $4.38 | -60.2% | -61.5% | +24.3% | +4.2% | +4.2% | +2.4% |
| Jan 6 | Stifel | Downgrade | Buy → Hold | — | $11.00 | $4.38 | -60.2% | -61.5% | +24.3% | +4.2% | +4.2% | +2.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | Valamehr Bahram | President and CEO | Sell | 28,946 | $1.88 | $54K | 635,762 | +7.14% | +7.98% |
| May 20, 2026 | TAHL CINDY | See Remarks | Sell | 25,590 | $1.88 | $48K | 628,155 | +7.14% | +7.98% |
8-K · 2.02
!! High
Fate Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Fate Therapeutics, Inc. -- 8-K Filing
Fate Therapeutics is advancing its iPSC-derived cellular immunotherapy pipeline toward Phase 2 trials, signaling progress in clinical development that could validate its off-the-shelf cell therapy platform's therapeutic potential.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 4,192,063 | $5M | New | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 4,134,585 | $5M | New | Mar 2026 |
| 3 | Acadian Asset Management Llc | 4,120,200 | $5M | Added | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 3,466,786 | $4M | Added | Mar 2026 |
| 5 | Johnson & Johnson | 3,379,064 | $4M | — | Mar 2026 |
| 6 | Aqr Capital Management Llc | 3,001,521 | $4M | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 2,974,683 | $4M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 1,821,715 | $2M | Added | Mar 2026 |
| 9 | Morgan Stanley | 1,833,892 | $2M | Reduced | Dec 2025 |
| 10 | Tang Capital Management Llc | 1,167,773 | $1M | Reduced | Dec 2025 |
| 11 | Citadel Advisors Llc | 942,926 | $1M | Added | Mar 2026 |
| 12 | Irenic Capital Management Lp | 878,055 | $1M | New | Mar 2026 |
| 13 | Northern Trust Corp | 811,920 | $974K | Added | Mar 2026 |
| 14 | Bruce & Co., Inc. | 789,188 | $947K | Added | Mar 2026 |
| 15 | Jane Street Group, Llc | 842,807 | $828K | Added | Dec 2025 |
| 16 | Monaco Asset Management Sam | 830,000 | $816K | Added | Dec 2025 |
| 17 | Man Group Plc | 430,073 | $516K | Added | Mar 2026 |
| 18 | Privium Fund Management B.v. | 414,311 | $497K | Added | Mar 2026 |
| 19 | Invesco Ltd. | 375,886 | $451K | Reduced | Mar 2026 |
| 20 | Nuveen, Llc | 339,073 | $407K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$248.3M
Enterprise Value
$117.9M
P/E (TTM)
-1.82x
Forward P/E
—
PEG Ratio
0.03x
P/B
1.20x
P/S
37.36x
P/FCF
-2.22x
EV/EBITDA
—
Shares Out
118.8M
Financials (TTM)
Revenue
$6.6M
Net Income
-$136.3M
EBITDA
-$127.0M
Free Cash Flow
-$112.0M
Op Cash Flow
-$106.1M
EPS Basic
$-1.15
EPS Diluted
$-1.15
EPS Forward
$-1.13
Gross Margin
-94.1%
Op Margin
-2222.4%
Net Margin
-2051.1%
Balance Sheet
Total Assets
$318.9M
Total Liab.
$111.8M
Total Equity
$207.2M
Cash
$203.7M
LT Debt
$73.3M
Book Value/Sh
$1.74
Debt/Equity
0.38x
Current Ratio
5.79
Quick Ratio
5.79
Returns & Growth
ROE
-65.8%
ROA
-42.7%
ROIC
-51.4%
Rev Growth YoY
-51.2%
EPS Growth YoY
+29.9%
Price Returns
2W
+49.5%
1M
+127.2%
3M
+91.9%
6M
+149.1%
12M
+134.7%
Technicals
52W High
$2.84
52W Low
$0.92
50d MA
$1.87
200d MA
$1.35
RSI (14)
25.20
ATR (14)
$0.21
Beta
2.24
Avg Volume
4.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$39.50
High
$145.00
Low
$3.00
Median
$7.50
Data updated apr 25, 2026 8:26am
· Source: financialmodelingprep.com